Did you mean aromatase inhibitor?
Displaying drugs 226 - 250 of 2437 in total
Sotorasib
Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.[A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... RAS GTPase Inhibitors ... P-glycoprotein inhibitors ... Immune Checkpoint Inhibitors …
Lenacapavir
HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens.[A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy in vitro, little to no cross-resistance...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (moderate) …
Reserpine
An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool,...
Approved
Investigational
Withdrawn
Matched Categories: … OCT1 inhibitors ... BSEP/ABCB11 Inhibitors ... Adrenergic Uptake Inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Levosimendan
Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Phosphodiesterase Inhibitors ... Phosphodiesterase 3 Inhibitors …
Nialamide
Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.
Approved
Withdrawn
Matched Categories: … Enzyme Inhibitors ... Monoamine Oxidase Inhibitors ... Monoamine Oxidase Inhibitors, Non-Selective …
Methazolamide
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Approved
Matched Categories: … Enzyme Inhibitors ... OAT1/SLC22A6 inhibitors ... Carbonic Anhydrase Inhibitors …
Diazepam
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and...
Approved
Illicit
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Oteseconazole
Oteseconazole is an azole metalloenzyme inhibitor that targets fungal CYP51. CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes.[L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... 14-alpha Demethylase Inhibitors …
Interferon alfacon-1
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Tocainide
An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (weak) …
Idoxuridine
An analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Nucleic Acid Synthesis Inhibitors ... Reverse Transcriptase Inhibitors …
Toremifene
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Cabazitaxel
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to...
Approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... OATP1B3 inhibitors ... Microtubule Inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Binimetinib
Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib.[A34275,L3335]
On June 27, 2018, the Food and Drug Administration approved the combination of Encorafenib and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients...
Approved
Investigational
Matched Categories: … Protein Kinase Inhibitors ... MAP Kinase, antagonists & inhibitors ... MAP Kinase Kinase 1, antagonists & inhibitors ... MAP Kinase Kinase 2, antagonists & inhibitors ... Mitogen-activated protein kinase (MEK) inhibitors …
Methoxsalen
A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) …
Rifampin
Rifampin, also known as rifampicin, is a broad-spectrum antimicrobial that was first discovered in 1965 and clinically used in 1968. Rifampin is used to treat tuberculosis and works by inhibiting the microbial DNA-dependent RNA polymerase (RNAP).
Approved
Matched Categories: … BSEP/ABCB11 Inhibitors ... Enzyme Inhibitors ... UGT1A9 Inhibitors ... OATP1B3 inhibitors ... OAT1/SLC22A6 inhibitors …
Thiotepa
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow...
Approved
Investigational
Matched Categories: … Cholinesterase Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors (moderate) …
Etoposide
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division,...
Approved
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... P-glycoprotein inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Penciclovir
Penciclovir is a synthetic acyclic guanine derivative with antiviral activity used for the treatment of various herpes simplex virus (HSV) infections. Displaying low toxicity and good selectivity, penciclovir is a nucleoside analogue.
Approved
Matched Categories: … Reverse Transcriptase Inhibitors ... Reverse Transcriptase Inhibitors ... Nucleic Acid Synthesis Inhibitors …
Amrinone
Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
Approved
Matched Categories: … Enzyme Inhibitors ... Phosphodiesterase Inhibitors ... Phosphodiesterase 3 Inhibitors …
Sacubitril
Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the FDA after being given the status of priority review for on July 7, 2015....
Approved
Matched Categories: … OATP1B3 inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Neprilysin, antagonists & inhibitors …
Dihydralazine
Dihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
Approved
Experimental
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Futibatinib
Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors …
Interferon beta-1a
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Zonisamide
Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of...
Approved
Investigational
Matched Categories: … Carbonic Anhydrase Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors (weak) …
Displaying drugs 226 - 250 of 2437 in total